SEC Looks Into Dendreon Following FDA Disclosure
Biotechnology company Dendreon Corp. said Tuesday that the U.S. Securities and Exchange Commission has opened an informal inquiry into the company's clinical trials for its prostate cancer drug, Provenge....To view the full article, register now.
Already a subscriber? Click here to view full article